SOUNDREEF
21.3.2024 20:10:32 CET | Business Wire | Press release
The European Court of Justice has issued a groundbreaking decision that opens the Italian copyright management market to Independent Management Entities. Soundreef, a leading independent management entity in Europe, celebrates this significant victory for the rights of authors, composers, and publishers to choose their representation in the copyright management sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321014981/en/
Davide d'Atri - Soundreef CEO (Photo: Business Wire)
The Court ruling reads:
“In its judgment, the Court replies that, in so far as the national legislation at issue does not allow independent management entities established in another Member State to provide their copyright management services in Italy, it constitutes a restriction on the freedom to provide services. Although that restriction may in principle be justified by the overriding objective of protecting intellectual property rights, it is not proportionate, as it generally and absolutely precludes any independent management entity established in another Member State from carrying out its activity in the market concerned. The Court points out that measures that are less restrictive of the freedom to provide services might enable the objective to be attained. Consequently, the Court finds that the Italian legislation at issue is not compatible with EU law.”
This decision highlights the importance of a liberalized market that welcomes private entities, promoting innovation and offering rightsholders improved management options.
Soundreef has played a crucial role in supporting this change over the last 10 years, together with industry partners, to ensure a more efficient, fair, and forward-looking copyright ecosystem. Soundreef is also the first independent management entity in Europe with a fully operational collection network, ready to leverage this new opportunity to enhance its services to authors, composers, and publishers.
Soundreef already represents over 43,000 songwriters and publishers globally, with 26,000 hailing from Italy. This includes stars such as Gigi D’Alessio, J-AX, Laura Pausini, Ultimo, Alejandro Sanz, and Sfera Ebbasta; heritage and contemporary writers like Giancarlo Bigazzi, Maurizio Fabrizio, Takagi & Ketra, and Federica Abbate; as well as some of the most important Italian rap artists and film and TV composers. In addition, SESAC Performing Rights has chosen Soundreef to represent its extensive repertoire in Italy, effective January 1, 2024. Founded in 1930, SESAC Performing Rights currently licenses the public performance of thousands of chart-topping songs on behalf of its top-tier affiliated songwriters and music publishers, which include such familiar names as Bob Dylan, Neil Diamond, Adele, Jack Harlow, Ariana Grande, Disclosure, Zac Brown, Rosanne Cash, Lee Brice, Margo Price, Nicky Jam, Blanco Brown, and many more. SESAC has also long represented the music on some of TV’s biggest shows including Grey’s Anatomy, How I Met Your Mother, A Million Little Things, Manifest, Dateline NBC, Dr. Phil, Seinfeld, and Modern Family, and is the PRO of choice among many of Hollywood’s most sought-after film and television composers including Christophe Beck, Danny Lux, The Newton Brothers, John Ehrlich, Gabriel Mann, Lili Haydn, and Guillermo Brown among others.
E-Lex is, from the very beginning, the law firm that assisted Soundreef in the main disputes in the field of copyright and copyright management. The team, initially led by Guido Scorza (now a member of the Italian Data Protection Authority), is now composed by Professor Giovanni Maria Riccio, the lawyer Adriana Peduto, partners in the firm, and the lawyer Dario Malandrino.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321014981/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
